Comprehensive Clinical Literature Review of Managing Bone Metastases in Breast Cancer: Focus on Pain and Skeletal-Related Events
- PMID: 38009875
- DOI: 10.1188/23.CJON.615-628
Comprehensive Clinical Literature Review of Managing Bone Metastases in Breast Cancer: Focus on Pain and Skeletal-Related Events
Abstract
Background: Bone metastases are the most common site of metastatic disease in breast cancer and can result in significant pain and an increased risk of skeletal-related events (SREs). Uncontrolled pain can further lead to negative outcomes.
Objectives: The aim is to provide oncology nurses with the latest evidence on the management of bone metastases in metastatic breast cancer (MBC) with a focus on pain and SREs.
Methods: A literature search was conducted using the Embase®, PubMed®/MEDLINE®, CINAHL®, and Cochrane Library databases. Clinical trials, retrospective studies, systematic reviews, meta-analyses, and practice guidelines, as well as one high-level conference abstract, were reviewed.
Findings: Options for managing bone metastases in MBC include surgical and interventional strategies, radiation, and bone-modifying agents. Management plans frequently include a combination of these modalities. More information is needed to better define the role of bone-directed therapies in MBC, particularly as they relate to nursing care.
Keywords: bone metastases; breast cancer; pain; pain management; symptom management.
Similar articles
-
Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.Clin Orthop Relat Res. 2021 Sep 1;479(9):2047-2057. doi: 10.1097/CORR.0000000000001749. Clin Orthop Relat Res. 2021. PMID: 33835092 Free PMC article.
-
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.J Clin Oncol. 2011 Mar 20;29(9):1221-7. doi: 10.1200/JCO.2010.32.5209. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343561
-
Analysis of denosumab on skeletal-related events in patients with advanced breast cancer.Clin J Oncol Nurs. 2015 Oct;19(5):E108-14. doi: 10.1188/15.CJON.E108-E114. Clin J Oncol Nurs. 2015. PMID: 26414586 Review.
-
Pharmacotherapy of bone metastases in breast cancer patients.Expert Opin Pharmacother. 2008 Apr;9(6):937-45. doi: 10.1517/14656566.9.6.937. Expert Opin Pharmacother. 2008. PMID: 18377337 Review.
-
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.J Clin Oncol. 2017 Dec 10;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16. J Clin Oncol. 2017. PMID: 29035643
Cited by
-
Balancing the Scales: The Dual Role of Interleukins in Bone Metastatic Microenvironments.Int J Mol Sci. 2024 Jul 26;25(15):8163. doi: 10.3390/ijms25158163. Int J Mol Sci. 2024. PMID: 39125732 Free PMC article. Review.
-
Extensive thoracic vertebral and chest wall metastases as the initial presentation of breast cancer: a case report and literature review.Front Oncol. 2025 Jul 17;15:1632700. doi: 10.3389/fonc.2025.1632700. eCollection 2025. Front Oncol. 2025. PMID: 40746598 Free PMC article. Review.
-
Alteration of BDNF and noradrenergic markers in locus coeruleus in a mouse model of cancer-induced bone pain.PLoS One. 2025 Aug 14;20(8):e0330207. doi: 10.1371/journal.pone.0330207. eCollection 2025. PLoS One. 2025. PMID: 40811566 Free PMC article.
-
Impact of Personalized Recovery Interventions on Spinal Instability and Psychological Distress in Oncological Patients with Vertebral Metastases.Diseases. 2025 Mar 16;13(3):85. doi: 10.3390/diseases13030085. Diseases. 2025. PMID: 40136625 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical